Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared to autologous approaches, leveraging healthy donor T cells engineered with multiplex gene-editing and proprietary lymphodepletion technologies. Key programs include cemacabtagene ansegedleucel (cema-cel) for frontline large B-cell lymphoma, ALLO-316 targeting clear cell renal cell carcinoma, and ALLO-329 for autoimmune conditions, with ongoing pivotal Phase 2 trials like ALPHA3 and RESOLUTION. Allogene Therapeutics Inc. maintains state-of-the-art in-house manufacturing and collaborates with partners such as Cellectis, Servier, and Arbor Biotechnologies to advance its pipeline. Headquartered in South San Francisco, California, the company operates a fully integrated platform from discovery through development, positioning it as a leader in redefining cell therapy accessibility for blood cancers, solid tumors, and autoimmune disorders.